1. Pink Sheet
  2. >>Vaccines

J&J Vaccine: Some CDC Advisors Question Warning’s Strength As Clot Reports Grow, Female Use Drops

 
• By Sarah Karlin-Smith

Some ACIP members argued woman older than 50 should also be singled out in warning for Johnson & Johnson’s COIVD-19 vaccine and said that people need to be more clearly told they can get alternative vaccines that don’t have this risk.

Johnson and Johnson COVID-19 vaccine
CDC advisors discussed updated safety data on J&J's COVID-19 vaccine on 12 May • Source: Valerio Rosati / Alamy Stock Photo

New updated US data on the rare blood clots seen in people who received Johnson & Johnson’s COVID-19 vaccine, including more reports in older people, caused some members of the Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices to push for stronger warnings on the vaccine at a 12 May meeting.

The CDC’s Vaccine Safety Technical Work Group, which includes ACIP member Grace Lee, is continuing to recommend that the benefits...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Vaccines

More from Pink Sheet

EMA’s PRIME Scheme Explored: Growing Designations - But Are Accelerated Assessments Slipping?

 
• By Neena Brizmohun

While the first six months of the year saw eight new drugs targeting a range of diseases enter the European Medicines Agency’s priority medicines scheme, and three PRIME-designated treatments go on to win EU marketing approval, use of the accelerated assessment mechanism appears to be limited.

Global Pharma Guidance Tracker - June 2025

 
• By Vibha Sharma and Anabel Costa-Ferreira

Stay up to date on regulatory guidelines from around the world with the Pink Sheet’s Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.

US FDA’s CRL Release More Incremental Than ‘Radical’ Transparency

 
• By Bridget Silverman

The transparency initiative collects CRLs already made public in approval packages on its drugs@fda site to post on the openFDA public portal.